Ethyl Chlorophenoxyisobutyrate

Ethyl Chlorophenoxyisobutyrate Uses, Dosage, Side Effects, Food Interaction and all others data.

A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

Ethyl Chlorophenoxyisobutyrate is an antilipidemic agent similar to gemfibrozil. It acts to lower elevated serum lipids by reducing the very low-density lipoprotein fraction (Sf 20-400) rich in triglycerides. Serum cholesterol may be decreased, particularly in those patients whose cholesterol elevation is due to the presence of IDL as a result of Type III hyperlipoproteinemia. Several investigators have observed in their studies that clofibrate may produce a decrease in cholesterol linoleate but an increase in palmitoleate and oleate, the latter being considered atherogenic in experimental animals. The significance of this finding is unknown at this time. Reduction of triglycerides in some patients treated with clofibrate or certain of its chemically and clinically similar analogs may be associated with an increase in LDL cholesterol. Increase in LDL cholesterol has been observed in patients whose cholesterol is initially normal. Animal studies suggest that clofibrate interrupts cholesterol biosynthesis prior to mevalonate formation.

Ethyl Chlorophenoxyisobutyrate
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Ethyl Chlorophenoxyisobutyrate
Availability	Discontinued
Generic	Clofibrate
Clofibrate Other Names	Clofibrate, Clofibrato, Clofibratum, EPIB, Ethyl chlorophenoxyisobutyrate, Ethyl clofibrate, Liprin
Related Drugs	Zetia, Praluent, Repatha, atorvastatin, simvastatin, rosuvastatin, Lipitor, ezetimibe, Crestor
Type
Formula	C₁₂H₁₅ClO₃
Weight	Average: 242.699 Monoisotopic: 242.070972053
Protein binding	Highly protein-bound (95% to 97%).
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ethyl Chlorophenoxyisobutyrate is a fibric acid derivative used to treat hypertriglyceridemia and high cholesterol.

For Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels.

How Ethyl Chlorophenoxyisobutyrate works

Ethyl Chlorophenoxyisobutyrate increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Ethyl Chlorophenoxyisobutyrate also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Also, as a fibrate, Ethyl Chlorophenoxyisobutyrate is an agonist of the PPAR-α receptor[4] in muscle, liver, and other tissues. This agonism ultimately leads to modification in gene expression resulting in increased beta-oxidation, decreased triglyceride secretion, increased HDL, increased lipoprotein lipase activity.

Toxicity

Oral, mouse: LD₅₀ = 1220 mg/kg; Oral, rabbit: LD₅₀ = 1370 mg/kg; Oral, rat: LD₅₀ = 940 mg/kg. No reported case of overdosage in humans.

Food Interaction

Take with food. Food decreases the risk of GI side effects.

Ethyl Chlorophenoxyisobutyrate Drug Interaction

Moderate: glipizide, glipizideMinor: furosemide, furosemideUnknown: erythromycin, erythromycin, ginkgo, ginkgo, acetylcysteine, acetylcysteine, acetaminophen, acetaminophen, valproic acid, valproic acid, pyridoxine, pyridoxine, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol

Ethyl Chlorophenoxyisobutyrate Disease Interaction

Major: cardiovascular effects, renal/liver disease, biliary cirrhosis, cholelithiasis, rhabdomyolysisModerate: PUD

Elimination Route

Completely but slowly absorbed from the intestine. Between 95% and 99% of an oral dose of clofibrate is excreted in the urine as free and conjugated clofibric acid; thus, the absorption of clofibrate is virtually complete.